ISSN online: 2995-7907

Medical Journal of Europe

Home

Issues

Submit

Guide

Pay

About

Contact

CONGRESS

Evaluation of Expanded Spectrum Beta-lactamase and Carbapenemase Positiveness of Enterobacteriaceae Members Grown in Blood Cultures at Hacettepe University Adult Hospital Between 2004 and 2012

Cite as:

Helvacı Ö, Zarakolu Köşker IP, Akova M. Evaluation of Expanded Spectrum Beta-lactamase and Carbapenemase Positiveness of Enterobacteriaceae Members Grown in Blood Cultures at Hacettepe University Adult Hospital Between 2004 and 2012. Med J Eur. 2024;2(2).68-74. doi: 10.5281/zenodo.10776791

ABSTRACT

The aim of this study was to determine extended-spectrum beta-lactamase (ESBL) and carbapenemase positivity of Enterobacteriaceae that grew in blood cultures and define the clinical properties of patients infected with carbapenemase positive strains. E.coli, K. pneumoniae, Enterobacter spp. and other Enterobacteriaceae in blood cultures between years 2004-2012 in Hacettepe University Faculty of Medicine were evaluated for ESBL and carbapenemase positivity. ESBL was defined with standard phenotypic method and carbapenemase with PCR for “VIM, IMP, KPC, NDM, OXA” carbapenemases. 382 of 1138 E. coli bacteremia (31.8%), 175 of 703 Klebsiella spp. bacteremias (24.8%) and 46 of 237 Enterobacter spp. bacteremias (24.8%) were ESBL positive. PCR was performed on 11 E. coli strains and 36 Klebsiella spp. strains. 7 of E. coli strains (63.6%) and 28 of Klebsiella spp. strains (77%) were carbapenemase positive. Klebsiella spp. subgroup analysis showed that 22 strains were OXA, 3 were VIM, 2 were IMP and one strain was OXA+VIM positive. For E.coli strains; 5 were OXA, 2 were OXA+VIM positive. NDM and KPC subtypes were detected. Our hospitals ESBL and/or carbapenemase positive Enterobacteriaceae frequency is similar with Europe and Turkey. In some years, there were sharp rises in ESBL producing bacteria rates , probably due to local epidemics. Resistance to antibiotics, increased mortality can be caused by these species. Since treatment options are limited, every precaution necessary should be taken to avoid spreading of resistant Enterobacteriaceae.

Keywords

Beta-lactamase, ESBL, carbapenemase, Enterobacteriaceae, healthcare associated infection.

mje-2024-2-68-74-helvaci-evaluation-of-expanded-spectrum-betalactamase-and-carbapenemase-positiveness-of-enterobacteriaceae-members-grown-in-blood-culturesDownload

REFERENCES

  1. Garrity GM. Bergey’s Manual Of Systematic Bacteriology, Volume 2, Part 3. FEMS Immunology & Medical Microbiology. 2005.
  2. Williams KP, Gillespie JJ, Sobral BWS, et al. Phylogeny of gammaproteobacteria. J Bacteriol. 2010;192:2305–2314.
  3. Denton M. Enterobacteriaceae. Int J Antimicrob Agents. 2007;29 Suppl 3:S9–S22. doi:10.1016/S0924-8579(07).80003-6
  4. Pitout JD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159–166. doi:10.1016/S1473-3099(08).70041-0
  5. Rupp ME, Fey PD. Extended spectrum beta-lactamase (ESBL).-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs. 2003;63:353–365. doi:10.2165/00003495-200363040-00002
  6. Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17:1791–1798. doi:10.3201/eid1710.110655
  7. Gur D, Hascelik G, Aydin N, et al. Antimicrobial resistance in gram-negative hospital isolates: results of the Turkish HITIT-2 Surveillance Study of 2007. J Chemother. 2009;21:383–389. doi:10.1179/joc.2009.21.4.383
  8. Gür D, Gülay Z, Akan OA, Aktaş Z, et al. Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study. Mikrobiyol Bul. 2008;42:537–544.
  9. Carrër A, Poirel L, Eraksoy H, Cagatay AA, Badur S, Nordmann P. Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. Antimicrob Agents Chemother. 2008;52:2950–2954. doi:10.1128/AAC.00527-08
  10. Carrër A, Poirel L, Yilmaz M, et al. Spread of OXA-48-encoding plasmid in Turkey and beyond. Antimicrob Agents Chemother. 2010;54:1369–1373. doi:10.1128/AAC.01559-09
  11. Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL). producing E. coli compared to non- ESBL producing E. coli. J Infect. 2007;55:254–259. doi:10.1016/j.jinf.2007.04.002
  12. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55:943–950. doi:10.1093/cid/cis588
  13. Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin Microbiol Infect. 2012;18:439–448. doi:10.1111/j.1469-0691.2012.03820.x
  14. Zarb P, Coignard B, Griskeviciene J, et al. The European Centre for Disease Prevention and Control (ECDC). pilot point prevalence survey of healthcare-associated infections and antimicrobial use. Euro Surveill. 2012;17(46).:20316. doi:10.2807/ese.17.46.20316-en
  15. Magill SS, Edwards JR, Bamberg W, et al. Multistate Point-Prevalence Survey of Health Care–Associated Infections. N Engl J Med. 2014;370:1198–1208. doi:10.1056/NEJMoa1306801
  16. Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: Here is the storm! Trends Mol Med. 2012;18:263–272. doi:10.1016/j.molmed.2012.03.003
  17. Frieden T. Antibiotic resistance threats. CDC. 2013.
  18. Turton JF, Ward ME, Woodford N, et al. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol Lett. 2006;258:272–7. doi:10.1111/j.1574-6968.2006.00195.x
  19. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9:228–236. doi:10.1016/S1473-3099(09).70054-4
  20. Rice LB. The clinical consequences of antimicrobial resistance. Curr Opin Microbiol. 2009;12:476–481. doi:10.1016/j.mib.2009.08.001
  21. Carattoli A, Miriagou V, Bertini A, Loli A, Colinon C, Villa L, et al. Replicon typing of plasmids encoding resistance to newer beta-lactams. Emerg Infect Dis. 2006;12:1145–1148. doi:10.3201/eid1207.051554
  22. Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Infect Control. 2006;34. doi:10.1016/j.ajic.2006.05.278
  23. Boucher HW, Talbot GH,  Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1–12. doi:10.1086/595011
  24. CDC. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep. 2013;62:165–170. doi:10.1016/j.ajic.2013.03.002
  25. Borgmann S, Wolz C, Gröbner S, et al. Metallo-β-lactamase expressing multi-resistant Acinetobacter baumannii transmitted in the operation area. J Hosp Infect. 2004;57:308–315. doi:10.1016/j.jhin.2004.03.019
  26. Crespo MP, Woodford N, Sinclair A, et al. Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia. J Clin Microbiol. 2004;42:5094–5101. doi:10.1128/JCM.42.11.5094-5101.2004
  27. (CDC). C for DC and P. Guidance for Control of Carbapenem-resistant Enterobacteriaceae 2012 CRE Toolkit. 2012. Available from: http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Guidance+for+Control+of+Carbapenem-resistant+Enterobacteriaceae+(+CRE+).+2012+CRE+Toolkit#0
  28. Tacconelli E, Cataldo MA, Dancer SJ, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014;20 Suppl 1:1-55. doi:10.1111/1469-0691.12427
  29. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55:943–950. doi:10.1093/cid/cis588
  30. R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41:848–854. doi:10.1086/432803
  31. Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemase- producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2011;55:3002–3004. doi:10.1128/AAC.01730-10
  32. Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother. 2008;52:570–573. doi:10.1128/AAC.00948-07
  33. Neuner EA, Yeh JY, Hall GS, et al. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis. 2011;69:357–362. doi:10.1016/j.diagmicrobio.2010.10.022
  34. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29:1099–1106. doi:10.1086/591861
  35. Hombach M, Bloemberg GV, Böttger EC. Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli. J Antimicrob Chemother. 2012;67:622–632. doi:10.1093/jac/dkr513
  36. Eser OK, Altun Uludağ H, Ergin A, Boral B, Sener B, Hasçelik G. [Carbapenem resistance in ESBL positive Enterobacteriaceae isolates causing invasive infections]. Mikrobiyol Bul. 2014;48:59–69. doi:10.5578/mb.6290
  37. Marchaim D, Zaidenstein R, Lazarovitch T, Karpuch Y, Ziv T, Weinberger M. Epidemiology of bacteremia episodes in a single center: increase in Gram- negative isolates, antibiotics resistance, and patient age. Eur J Clin Microbiol Infect Dis. 2008;27:1045–1051. doi:10.1007/s10096-008-0541-2
  38. Marschall J, Doherty J, Warren DK. The epidemiology of recurrent Gram- negative bacteremia in a tertiary-care hospital. Diagn Microbiol Infect Dis. 2010;66:456–459. doi:10.1016/j.diagmicrobio.2009.12.021
  39. Högenauer C, Langner C, Beubler E, et al. Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. N Engl J Med. 2006;355:2418–2426. doi:10.1056/NEJMoa054765
  40. Yilmaz E, Uraz G. [Detectıon Of Extended-Spectrum Beta Lactamase In Klebsiella Pneumonıae And Klebsiella Oxytoca Bacterıa Wıth Combıned Dısc Method]. 2011;15(1).:41–45.
  41. Yavuz MT, Ersan G, Süvarierel M. [Investigation of Extended Spectrum Beta- Laktamase Activity of Enterobacteriaceae Strains by Using Two Different Methods]. Duzce Med J. 2005;7(2).:10-13.
  42. Kaye KS, Cosgrove S, Harris A, Eliopoulos GM, Carmeli Y. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother. 2001;45:2628–2630. doi:10.1128/AAC.45.9.2628-2630.2001
  43. Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: Results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). Diagn Microbiol Infect Dis. 2012;73:354–360. doi:10.1016/j.diagmicrobio.2012.05.015
  44. Van der Bij AK, Pitout JDD. The role of international travel in the worldwide spread of multiresistant Enterobacteriaceae. J Antimicrob Chemother. 2012;67:2090–2100. doi:10.1093/jac/dks214
  45. Poirel L, Héritier C, Tolün V, Nordmann P. Emergence of oxacillinase- mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2004;48:15–22. doi:10.1128/AAC.48.1.15-22.2004
  46. Korten V, Ulusoy S, Zarakolu P, Mete B. Antibiotic resistance surveillance over a 4-year period (2000-2003). in Turkey: results of the MYSTIC Program. Diagn Microbiol Infect Dis. 2007;59:453–7. doi:10.1016/j.diagmicrobio.2007.07.008
  47. Aktas Z, Bal C, Midilli K, Poirel L, Nordmann P. First IMP-1-producing Klebsiella pneumoniae isolate in Turkey. Clin Microbiol Infect. 2006;12(7).:695–696. doi:10.1111/j.1469-0691.2006.01493.x
  48. Ozgumus OB, Caylan R, Tosun I, Sandalli C, Aydin K, Koksal I. Molecular epidemiology of clinical Pseudomonas aeruginosa isolates carrying IMP-1 metallo-beta-lactamase gene in a University Hospital in Turkey. Microb Drug Resist. 2007;13(3).:191–8. doi:10.1089/mdr.2006.13.191
  49. Iraz M, Duzgun AO, Cicek AC, Saral A, et al. Characterization of novel VIM carbapenemase, VIM-38, and first detection of GES-5 carbapenem-hydrolyzing β-lactamases in Pseudomonas aeruginosa in Turkey. Diagn Microbiol Infect Dis. 2014;78(3).:292–294. doi:10.1016/j.diagmicrobio.2014.02.010
  50. Yildirim I, Ceyhan M, Gur D, Mugnaioli C, Rossolini GM. First detection of VIM-1 type metallo-beta-lactamase in a multidrug-resistant Klebsiella pneumoniae clinical isolate from Turkey also producing the CTX-M-15 extended-spectrum beta-lactamase. J Chemother. 2007;19(4).:467–468. doi:10.1179/joc.2007.19.4.467

MJE-029

editor@medjeur.com